NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.2789 -0.01 (-3.46 %) (As of 01/20/2019 01:55 PM ET)Previous Close$0.2789Today's Range$0.26 - $0.3052-Week Range$0.07 - $2.80Volume7.39 million shsAverage Volume16.01 million shsMarket Capitalization$69.18 millionP/E RatioN/ADividend YieldN/ABeta3.02 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Receive SGYP News and Ratings via Email Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGYP Previous Symbol CUSIP87163930 Webwww.synergypharma.com Phone212-297-0020Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.82 million Price / Sales4.11 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-13.95Profitability EPS (Most Recent Fiscal Year)($1.02) Net Income$-224,330,000.00 Net Margins-332.11% Return on EquityN/A Return on Assets-118.14%Miscellaneous Employees313 Outstanding Shares248,040,000Market Cap$69.18 million OptionableOptionable Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions What is Synergy Pharmaceuticals' stock symbol? Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP." How were Synergy Pharmaceuticals' earnings last quarter? Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $11.11 million during the quarter, compared to the consensus estimate of $15.65 million. View Synergy Pharmaceuticals' Earnings History. When is Synergy Pharmaceuticals' next earnings date? Synergy Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Synergy Pharmaceuticals. What price target have analysts set for SGYP? 5 analysts have issued twelve-month price targets for Synergy Pharmaceuticals' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $8.00 in the next year. This suggests a possible upside of 2,768.4% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals. What is the consensus analysts' recommendation for Synergy Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals. Has Synergy Pharmaceuticals been receiving favorable news coverage? Press coverage about SGYP stock has trended extremely positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Synergy Pharmaceuticals earned a news impact score of 4.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. Are investors shorting Synergy Pharmaceuticals? Synergy Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 16,520,891 shares, a decrease of 63.6% from the December 14th total of 45,331,866 shares. Based on an average trading volume of 19,706,792 shares, the short-interest ratio is presently 0.8 days. Approximately 6.7% of the shares of the stock are sold short. View Synergy Pharmaceuticals' Current Options Chain. Who are some of Synergy Pharmaceuticals' key competitors? Some companies that are related to Synergy Pharmaceuticals include Minerva Neurosciences (NERV), Kadmon (KDMN), Marker Therapeutics (MRKR), Catalyst Pharmaceuticals (CPRX), Verrica Pharmaceuticals (VRCA), Urovant Sciences (UROV), Aclaris Therapeutics (ACRS), Savara (SVRA), Verastem (VSTM), Tyme Technologies (TYME), Intec Pharma (NTEC), Adamas Pharmaceuticals (ADMS), Axsome Therapeutics (AXSM), AVEO Pharmaceuticals (AVEO) and Acer Therapeutics (ACER). Who are Synergy Pharmaceuticals' key executives? Synergy Pharmaceuticals' management team includes the folowing people: Mr. Troy Hamilton Pharm.D., CEO & Director (Age 47)Mr. Gary G. Gemignani, Exec. VP & CFO (Age 54)Gem Gokmen Hopkins, VP of Investor Relations and Corp. CommunicationsMs. Pam Cebulski, Sr. VP of MarketingMs. Marianne Jackson, Sr. VP of Sales & Market Access How do I buy shares of Synergy Pharmaceuticals? Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Synergy Pharmaceuticals' stock price today? One share of SGYP stock can currently be purchased for approximately $0.2789. How big of a company is Synergy Pharmaceuticals? Synergy Pharmaceuticals has a market capitalization of $69.18 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe. What is Synergy Pharmaceuticals' official website? The official website for Synergy Pharmaceuticals is http://www.synergypharma.com. How can I contact Synergy Pharmaceuticals? Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected] MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 637 (Vote Outperform)Underperform Votes: 340 (Vote Underperform)Total Votes: 977MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: What is Compound Interest?